[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100579695":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":33,"centralContacts":38,"locations":47,"responsibleParty":62,"collaborators":10,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":66,"sex":72,"minAge":73,"maxAge":10,"enrollmentInfo":74,"targetDuration":10,"studyType":77,"phases":10,"briefSummary":78,"conditions":79,"keywords":85,"overallStatus":100,"whyStopped":10,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},{"fullName":5,"class":6},"Assistance Publique Hopitaux De Marseille","OTHER",[8,15,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort 1 - Patients with solid tumor undergoing surgery",null,"Cohort 1 (patients with solid tumor undergoing surgery):\n\n* Head and neck cancer: up to 80 patients\n* Urologic cancer: up to 160 patients\n* Liver cancer: up to 80 patients\n* Colorectal and gastric cancer: up to 80 patients\n* Breast cancer: up to 80 patients\n\nA maximum of 3 visits are planned :\n\n* Screening visit for patient evaluation and inclusion\u002Fexclusion criteria review\n* Visit 1: For blood sampling specifically for the study\n* Visit 2: For tumor sampling and blood sampling if not done at Visit 1 Fresh solid tumor lesions and normal adjacent tissue will be macroscopically selected from the resected tumor material by a pathologist. Samples will be collected according to decision of May 3, 2017 establishing a list of researches as mentioned by article L1121-1, paragraph 2° of the French public Health code, and will therefore only concern blood samples, as well tissues collected during surgeries.\n\nThe Screening visit and the Visit 1 can occur on the same day.",[13,14],"Procedure: blood collection","Procedure: tissue specimen collection",{"label":16,"type":10,"description":17,"interventionNames":18},"Cohort 2 - Patients with solid tumor with anti-PD1\u002FPD-L1 treatment and no surgery","* Lung cancer: up to 40 patients\n* Head and neck cancer: up to 40 patients a maximum of 3 visits are planned during this period:\n* A Screening visit for patient evaluation and inclusion\u002Fexclusion criteria review.\n* A Baseline visit (pre-treatment) visit for blood sampling specifically for the study\n* A post-treatment visit (after immunotherapy administration) for blood sampling specifically for the study The Screening and Baseline visits can occur on the same day.",[13],{"label":20,"type":10,"description":21,"interventionNames":22},"Cohort 3 - Patients with hematological malignancies","\\- Lymphoma and leukemia: up to 80 patients\n\nA maximum of 2 visits are planned during this period:\n\n* A Screening visit\n* Visit 1: for blood sampling specifically for the study The Screening visit and the Visit 1 could occur on the same day.",[13],[24,29],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":10},"PROCEDURE","blood collection","Blood sampling is performed during Scrrening \u002F visit 1 for patients enrolled in cohort 1, cohort 2 and cohort 3",[9,16,20],{"type":25,"name":30,"description":31,"armGroupLabels":32,"otherNames":10},"tissue specimen collection","In Cohort 1- patients with solid tumor undergoing surgery, fresh tissue specimen is collected during surgery",[9],[34],{"name":35,"affiliation":36,"role":37},"Frederic VELY, Dr","Assistance Publique Hôpitaux de Marseille","PRINCIPAL_INVESTIGATOR",[39,43],{"name":35,"role":40,"phone":41,"phoneExt":10,"email":42},"CONTACT","0491384396","frederic.vely@ap-hm.fr",{"name":44,"role":40,"phone":45,"phoneExt":10,"email":46},"Mathilde LEFEVRE,, Director","0491382778","mathilde.lefevre@ap-hm.fr",[48],{"facility":49,"status":10,"city":50,"state":10,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"Hopital Timone enfants - plateforme d'Immunoprofiling","Marseille","13385","France","FR",{"type":55,"coordinates":56},"Point",[57,58],5.38107,43.29695,{"lat":58,"lon":57},[61],{"name":35,"role":40,"phone":41,"phoneExt":10,"email":42},{"type":63,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100579695","in-depth-characterization-of-circulating-and-infiltrating-immune-subsets-and-tumor-cells-in-cancer-patients-100579695",false,"NCT06827639","In-depth Characterization of Circulating and Infiltrating Immune Subsets and Tumor Cells in Cancer Patients","In-depth Characterization of Circulating and Infiltrating Immune Subsets and Tumor Cells in Cancer Patients.","FUTURE","Inclusion Criteria:\n\n* 18 years of age or older\n* Histologic, cytologic or imaging confirmation of a malignancy in accordance with targeted indications\n* Written informed consent signed from subject prior to performing any protocol-related procedures\n\nExclusion Criteria:\n\n* Use of any investigational agent within 14 days prior first visit;\n* Patient under guardianship\u002Ftrusteeship or legally incapacitated person;\n* Patient unable to understand read and\u002For sign an informed consent;\n* Uncooperative or potentially non-compliant for the study or study procedures patient, or with foreseeable regular follow-up difficulties;\n* Patient without Health insurance scheme or Universal Medical Coverage (CMU) or any equivalent scheme;\n* Patients who are known to be HIV positive","ALL","18 Years",{"count":75,"type":76},640,"ESTIMATED","OBSERVATIONAL","The aim of this study is to describe the tumor microenvironment of solid tumors and to understand the changes induced by anti-cancer treatments, particularly those developed by Innate Pharma. Innate Pharma is a biotechnology company which discovers and develops therapeutic antibodies that exploit the innate immune system to improve cancer treatment. Thanks to this study, it will be possible to correlate clinical and immunological characteristics with the patient\\'s clinical features. The analyses generated will contribute to the design and improvement of innovative therapeutic antibodies acting on the immune system",[80,81,82,83,84],"Head and Neck Cancer","Urologic Cancer","Lung Cancer","Breast Cancer","Liver Cancer",[86,87,88,89,90,91,92,93,94,95,96,97,98,99],"Tumor microenvironment","Immuno-phenotyping","Immunohistochemistry","Ex-vivo functional assays","circulating tumor DNA","Gene sinatures","Breast cancer","Head and neck cancer","Urologic cancer","Liver cancer","Colorectal and gastric cancer","Lung cancer","lymphoma","leukemia","NOT_YET_RECRUITING","2025-02-13",{"date":103,"type":104},"2025-02-14","ACTUAL",{"date":106,"type":76},"2025-04-30",{"date":108,"type":76},"2028-04-30",{"name":5,"class":6},1]